AbbVie Inc (NYSE: ABBV), a research-driven biopharmaceutical company, announced on Friday the decision by its board of directors to increased the company's quarterly cash dividend by 11% from USD0.64 per share to USD0.71 per share.
This increased cash dividend is payable on 15 February 2018 to shareholders of record at the close of business on 12 January 2018.
Since the company's inception in 2013, AbbVie said it has increased its dividend by over 77%.
AbbVie works in the four primary therapeutic areas of immunology, oncology, virology and neuroscience.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development